Iffeza
- Procedure started
- Under evaluation
- CHMP opinion
- European Commission final decision
Table of contents
Overview
On 19 April 2012, the European Medicines Agency completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicines Flutiform and Iffeza and associated names. The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Flutiform and Iffeza outweigh the risks, and that the marketing authorisation can be granted in the United Kingdom and in the following Member States of the EU: Austria, Belgium, Bulgaria, Cyprus, the Czech Republic, Denmark, Finland, France, Germany, Iceland, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia and Sweden.
Key facts
Approved name |
Iffeza
|
International non-proprietary name (INN) or common name |
|
Associated names |
|
Reference number |
EMEA/H/A-29/001327
|
Type |
Article 29(4) referrals
This type of referral is triggered when there is a disagreement between Member States regarding a marketing authorisation application being evaluated in a mutual-recognition or decentralised procedure, on the grounds of a potential serious risk to public health. |
Status |
European Commission final decision
|
Opinion date |
19/04/2012
|
EC decision date |
28/06/2012
|
All documents
-
List item
Questions and answers on Flutiform and Iffeza (fluticasone propionate / formoterol fumarate, 50/5, 125/5 and 250/10 micrograms, pressurised inhalation, suspension) (PDF/66.23 KB)
First published: 20/04/2012
Last updated: 25/10/2012
EMA/264710/2012 Rev.1 -
-
List item
Iffeza - Article 29 referral - Assessment report (PDF/128.12 KB)
Adopted
First published: 25/10/2012
Last updated: 25/10/2012
EMA/399722/2012 -
List item
Iffeza - Article 29 referral - Annex I (PDF/177.61 KB)
First published: 25/10/2012
Last updated: 25/10/2012 -
-
List item
Iffeza - Article 29 referral - Annex II (PDF/85.05 KB)
First published: 25/10/2012
Last updated: 25/10/2012 -
-
List item
Iffeza - Article 29 referral - Annex III (PDF/16.33 KB)
First published: 25/10/2012
Last updated: 25/10/2012 -
Document description
- Questions and answers (Q&A) - easy-to-understand summary of key issues and Committee conclusions
- Summary of Opinion - contains the CHMP opinion of the referred medicine(s)
- List of the medicines affected by the referral (Annex I)
- Scientific conclusions of the Committee (Annex II)
The following two documents are sometimes available:
- Changes to the summary of product characteristics, labeling or package leaflet (also known as Annex III) - available when changes havebeen recommended by the Committee
- Conditions of the marketing authorisation (also known as Annex IV) - available when the Committee recommends measures to be taken for the marketing authorisation(s) such as safety measures or extra studies